FDA may pull authorization of Pfizer’s Covid vaccine for children under 5

FDA may pull authorization of Pfizer’s Covid vaccine for children under 5


A nurse prepares doses of the Pfizer vaccine during a COVID-19 vaccination event at Josephine’s Southern Cooking in Chatham, Illinois, Dec. 30, 2021.

Brian Cassella | Tribune News Service | Getty Images

The Food and Drug Administration is weighing revoking its authorization of Pfizer‘s Covid-19 vaccine for healthy children under the age of 5, the drugmaker confirmed to CNBC on Tuesday. 

The move could leave many kids with no available shot against the virus, as jabs from Moderna and Novavax are cleared for more limited populations. While Covid typically causes mild symptoms in most children, others, such as infants under 1 or those with certain health conditions, can be at a higher risk of severe illness and hospitalization.

If the FDA pulls the authorization, it would add to a string of recent efforts by U.S. health agencies to change and undermine immunization policy since Health and Human Services Secretary Robert F. Kennedy Jr. — a prominent vaccine skeptic — took the helm. HHS did not immediately respond to a request for comment.

The FDA told Pfizer it might not renew its longstanding emergency use authorization for children aged 6 months to 4 years, the company said in a statement. Pfizer said it has requested the authorization to remain in place for the upcoming fall and winter season and is “currently in discussions with the agency on potential paths forward.”

The company said that the FDA’s “deliberations” are not related to the safety and efficacy of the shot, “which continues to demonstrate a favorable profile.”

The Guardian first reported on the FDA’s potential move. Moderna is working with the Centers for Disease Control and Prevention to boost supplies of its own Covid shot for children, the Guardian reported on Saturday.

In July, the FDA granted full approval to Moderna’s Covid vaccine for children — but only for those with health conditions that may put them at increased risk of severe illness if they become infected. Both shots from Moderna and Pfizer user messenger RNA technology.

Kennedy has targeted those vaccines in the past, filing a petition in May 2021 demanding that the agency revoke authorization of the jabs.  

Meanwhile, Novavax‘s protein-based shot has never been available for children under 12. 

In May, Kennedy announced that the Centers for Disease Control and Prevention has removed its recommendation of Covid vaccines for healthy children and pregnant women. 

But in updated guidance days later, the CDC said the shots “may” be given to those kids if a doctor agreed that it was necessary. Covid vaccines during pregnancy are now listed as “No Guidance/Not Applicable,” where they were previously recommended for all pregnant adults.



Source

Trump signs executive order reclassifying cannabis, opening door to broader weed access
Health

Trump signs executive order reclassifying cannabis, opening door to broader weed access

U.S. President Donald Trump sits in the Oval Office to sign executive orders, at the White House in Washington, D.C., U.S., Dec. 18, 2025. Evelyn Hockstein | Reuters President Donald Trump signed an executive order Thursday directing federal agencies to reclassify marijuana, loosening long-standing restrictions on the drug and marking the most consequential shift in […]

Read More
Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound 
Health

Eli Lilly says obesity pill helps maintain weight loss after patients switch from Wegovy, Zepbound 

Eli Lilly on Thursday said its closely watched obesity pill helped patients maintain the majority of their weight loss after they switched directly from taking the company’s injection Zepbound and Novo Nordisk’s rival shot Wegovy in a late-stage trial.  The company also said it has filed for Food and Drug Administration approval of the daily […]

Read More
Medical supply firm Medline set to debut after biggest IPO of 2025
Health

Medical supply firm Medline set to debut after biggest IPO of 2025

U.S. medical supplies giant Medline is set to debut on the Nasdaq on Wednesday after the biggest initial public offering of the year.  The private equity-owned company priced at $29 per share on Tuesday, raising $6.26 billion in an upsized offering that finishes off a strong year for new listings and bolsters optimism about the […]

Read More